Telomir Pharma says preclinical results in worm models indicate its drug shows potential to improve longevity and healthspan.
Preclinical stage longevity biotech Telomir Pharmaceuticals has announced progress in its ongoing research into the science of age-reversal. The company, which is developing small molecules designed to lengthen telomeres and protect DNA from degradation, revealed preclinical results in the nematode Caenorhabditis elegans (C. elegans), a widely studied model organism in aging research.
Telomeres, the protective end caps of chromosomes, prevent genetic material from deteriorating during cell division. As cells replicate, telomeres shorten, leaving DNA vulnerable to damage and loss. This shortening process contributes to aging and the onset of degenerative diseases. The telomerase enzyme helps maintain telomeres, though its activity diminishes with age, exacerbating telomere erosion and its associated effects.
Telomir aims to intervene in the telomere-shortening process using a small molecule approach. The company’s lead compound, Telomir-1, is designed to modulate telomerase to promote the repair and lengthening of telomeres.
The recent preclinical study leveraged technology developed by Nagi Bioscience to enable precise, automated tracking of healthspan, lifespan, and mobility metrics of the C. Elegans organism. Telomir claims that treatment with its drug “significantly” enhanced these parameters in the nematodes, suggesting the results amounted to a measurable reversal of biological aging.
Specific metrics regarding the magnitude of improvements were not disclosed, and it should be noted that translating early-stage research results in C. Elegans into other model organisms and ultimately into humans is far from guaranteed.
Building on these early findings, Telomir says it is expanding its research to address specific age-related conditions, including progeria, a rare genetic disorder causing accelerated aging in children. In collaboration with the Progeria Foundation, the company is investigating Telomir-1’s effects on human progeria cell lines, aiming to assess its ability to counteract cellular aging. Concurrently, Telomir says it also plans an in vivo study using a progeria C. elegans model.
